How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
BridgeBio Pharma is back in focus after its fair value estimate was lifted from $89.79 to $100.05, an increase of about 11% that resets the conversation around upside and risk. That move aligns with analyst commentary pointing to support from Attruby's recent net sales and growing expectations around the broader late stage pipeline. As you read on, you will see how these shifting targets, along with the bullish and cautious arguments behind them, can help you track the evolving narrative around BridgeBio Pharma. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value BridgeBio Pharma. What Wall Street Has Been Saying ?? Bullish Takeaways Multiple firms, including Truist, Morgan Stanley, Evercore ISI, H.C. Wainwright and BofA, have raised price targets through early 2026, signaling increased confidence in BridgeBio Pharma's setup. Truist, Evercore ISI and Oppenheimer point to Attruby, with Q4 net sales of US$146m a
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]Yahoo! Finance
- BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9GlobeNewswire
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 3/16/26 - Form 4
- 3/13/26 - Form 144
- 3/12/26 - Form 4
- BBIO's page on the SEC website